Trials / Withdrawn
WithdrawnNCT00821561
A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects
A Phase 2, Randomized, Prospective, Double-masked, Vehicle-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Nexagon® in Subjects With Persistent Corneal Epithelial Defects (PED) From Chemical Burn Injuries.
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- OcuNexus Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nexagon® | |
| DRUG | Nexagon® vehicle |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-11-01
- Completion
- 2010-03-01
- First posted
- 2009-01-13
- Last updated
- 2010-02-26
Source: ClinicalTrials.gov record NCT00821561. Inclusion in this directory is not an endorsement.